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Abstract
Background Both primary and secondary gynaecological
neuroendocrine (NE) tumours are uncommon, and the litera-
ture is scarce concerning their imaging features.
Methods This article reviews the epidemiological, clinical
and imaging features with pathological correlation of
gynaecological NE tumours.
Results The clinical features of gynaecological NE tumours
are non-specific and depend on the organ of origin and on the
extension and aggressiveness of the disease. The imaging ap-
proach to these tumours is similar to that for other histological
types and the Revised International Federation of Gynecology
and Obstetrics (FIGO) Staging System also applies to NE
tumours. Neuroendocrine tumours were recently divided into
two groups: poorly differentiated neuroendocrine carcinomas
(NECs) and well-differentiated neuroendocrine tumours
(NETs). NECs include small cell carcinoma and large cell
neuroendocrine carcinoma, while NETs account for typical
and atypical carcinoids. Cervical small cell carcinoma and
ovarian carcinoid are the most common gynaecological NE
tumours. The former typically behaves aggressively; the latter
usually behaves in a benign fashion and tends to be confined
to the organ.
Conclusion While dealing with ovarian carcinoids, extra-
ovarian extension, bilaterality and multinodularity raise the
suspicion of metastatic disease. NE tumours of the endome-
trium and other gynaecological locations are very rare.
Teaching Points
• Primary or secondary neurondocrine (NE) tumours of the
female genital tract are rare.
• Cervical small cell carcinoma and ovarian carcinoids are
the most common gynaecological NE tumours.
• Cervical small cell carcinomas usually behave aggressively.
• Ovarian carcinoids tend to behave in a benign fashion.
• The imaging approach to gynaecological NE tumours and
other histological types is similar.
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Introduction
Neuroendocrine tumours comprise a set of neoplasms that
arises from the diffuse neuroendocrine cell system. These tu-
mours are more commonly identified in the gastrointestinal
tract, pancreas, lung and thymus. Gynaecological NE tumours
are uncommon, either as primary or secondary tumours [1].
Recently, a simplified terminology has been proposed, di-
viding NE tumours in two groups: poorly differentiated neu-
roendocrine carcinomas (NECs) and well-differentiated neu-
roendocrine tumours (NETs). NECs include small cell carci-
noma and large cell neuroendocrine carcinoma, while NETs
account for typical and atypical carcinoids [1–4].
The most prevalent gynaecological NE tumours are cervi-
cal small cell carcinoma and ovarian carcinoids. Elsewhere in
the female genital tract, NECs or NETs are rare or nonexistent
[5]. The clinical features of gynaecological NE tumours gen-
erally depend on the organ of origin and are non-specific.
However, some patients may present with paraneoplastic syn-
dromes owing to the production of several peptides and hor-
mones. The absence of endocrine clinical syndromes in most
patients with NE tumours is possibly related to the release of
insufficient amounts or inactive hormones [6].
The purpose of this article is to review the epidemiological,
clinical and imaging features with pathological correlation of
primary gynaecological NE tumours, emphasising the impor-
tance of differentiating them frommetastatic disease and other
carcinomas with an NE component.
General histological considerations
For the classification of NE differentiation, tumour cells have
to express at least two NE markers such as chromogranin A,
synaptophysin or neuron-specific enolase. A great variety of
other peptides and hormones may be found, including calci-
tonin, gastrin, serotonin, substance P, vasoactive intestinal
peptide, pancreatic polypeptide, somatostatin and adrenocor-
ticotrophic hormone [1, 3].
Some cancers display a combination of NE and non-NE
features, usually either glandular or squamous components.
The amount of NE component within a non-NE carcinoma
may range from a single NE cell to a well-identifiable NE
tumour cell population. In this set, two terms are widely ac-
cepted: mixed exocrine-endocrine carcinoma (MEEC) and
(adeno)carcinoma with (focal) NE differentiation. The finding
of a focal non-NE differentiation in almost pure NE tumours is
less common [7].
According to the World Health Organisation (WHO) classifi-
cation of NE tumours, the diagnosis of a mixed exocrine-
endocrine tumour should take into account at least two major
diagnostic parameters: an extension of at least 30 % for each
component and the recognition of structural NE features such
as well-differentiated organoid or solid/diffuse growth patterns.
In fact, no reasonable explanation is provided for the limit of
30 %, and consequently morphological criteria should also be
considered [7, 8].
Carcinomaswith focal NE differentiation have been identified
in several non-NE tumours of the gynaecological tract, such as
endometrial endometrioid adenocarcinomas, endocervical ade-
nocarcinomas and adenosquamous carcinomas, and even ovari-
an surface epithelial neoplasms of mucinous, endometrioid and
serous types. These tumours display less than one-third of NE
cells and a non-NE growth pattern, and the finding of these NE
cells has not been shown to affect outcome [5, 7].
Few data are currently at our disposal regarding the prog-
nosis of mixed exocrine-endocrine carcinoma (MEEC) in
comparison to pure NE or non-NE tumours. However, the
therapeutic schemes are different and the accurate histological
diagnosis is mandatory.
The diagnosis of an NE tumour may be challenging. The
differentiation of small cell NE carcinomas from poorly dif-
ferentiated squamous cell carcinoma (SCC) with NE features
may be especially difficult. Sometimes, and particularly for
cervical cancers, the recognition of the NE component is only
possible after the hysterectomy, since the tissue obtained on
cervical biopsymay be insufficient, leading to the diagnosis of
poorly differentiated cervical cancer.
General imaging considerations
Due to the rarity of these tumours, data in the literature
concerning their imaging features are scarce. We know that
small cell carcinoma and large cell NE carcinoma tend to
behave aggressively, in contrast to carcinoids, which are typ-
ically confined to the organ. Nevertheless, these are non-
specific features and the available data regarding these ex-
tremely rare tumours are limited and discourage scientific
generalisations. Consequently, no reliable guidelines, for ei-
ther diagnosis or treatment, are established. For staging pur-
poses, physicians and radiologists should consider the current-
ly used Revised International Federation of Gynecology and
Obstetrics (FIGO) Staging System [9–11].
The imaging approach to gynaecological NE tumours is sim-
ilar to that for other histological types. For the cervix, uterus and
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adnexa, ultrasound (US) using both transabdominal and
transvaginal probes plays a critical role in the initial diagnosis.
The use of computed tomography (CT) or positron emission
tomography-computed tomography (PET-CT) is established in
cervical and endometrial tumours for detection of nodal and
distant metastases, which may be particularly useful for poorly
differentiated NE carcinomas, typically invasive and metastatic.
In ovarian cancers, CT is also indicated to evaluate the extent of
disease and detect nonresectable metastases. Magnetic reso-
nance imaging (MRI) may be used for characterising indetermi-
nate adnexal masses and for pre-treatment staging purposes, es-
sentially in cervical and endometrial tumours. MRI may re-
place CT in the staging of adnexal tumours in young
females, pregnancy, renal insufficiency and allergy to
iodinated contrast [10, 12, 13] (Table 1).
NE tumours of the vagina and vulva are much rarer. US
plays a limited role in the diagnosis, but CT and MRI may be
used for staging purposes. MRI is primarily used for local
staging of vaginal tumours and should be performed after
vaginal filling with gel [11].
Particularly for typical and atypical carcinoids (well-differ-
entiated neuroendocrine tumours), an octreotide scan may be
used. This is a somatostatin analogue scintigraphy that as-
sesses relevant receptor expression in vivo. Patients with neg-
ative octreotide scans should not be considered for somato-
statin analogue therapy and typically show better responses to
chemotherapy schemes [1].
Ovary
The most common NE tumours of the ovary are typical carci-
noid tumours. Atypical carcinoids and poorly differentiated
NE carcinomas (NECs) are very rare.
Well-differentiated neuroendocrine tumours (NETs)
Primary carcinoid tumours of the ovary are rare and account
for less than 5 % of all carcinoid tumours and for less than
0.1 % of all ovarian neoplasms. These are germ cell tumours
in origin and classified as teratomas with a predominance of
NE features. The great majority is asymptomatic and inciden-
tally found on cross-sectional or ultrasound imaging. The me-
dian age of diagnosis is 55 years of age (range from 17 to
83 years), with most of the patients being peri- or postmeno-
pausal [1, 14–17].
These tumours are typically unilateral, slow growing and
diagnosed in an early stage. In a 5-decade analysis performed
by Modlin et al. [18], 66 % of 113 carcinoid ovarian tumours
were localised lesions, while 22 %–31 % presented with dis-
tant spread. They may exist in pure forms, predominantly
solid with small cysts or as a nodule within a mature teratoma,
mucinous cystadenoma or even Brenner tumour [19].
Four distinct histological subtypes are described: insular,
trabecular, mucinous and strumal. Ovarian carcinoids contain
well-differentiated NE cells and some subtypes are similar to
the gastrointestinal carcinoids. They are immunoreactive to at
least one neuroendocrine marker, including chromogranin,
synaptophysin or Leu-7, and may also be present in peptide
hormones such as pancreatic polypeptide, gastrin, vasoactive
intestinal peptides and glucagon [14].
Insular carcinoid is the most common type of ovarian car-
cinoid, typically presenting with a pelvic mass. Near 30 % of
patients will have signs and symptoms of carcinoid syndrome,
including facial flushing, diarrhoea, bronchospasm and oede-
ma [20]. It happens because serotonin-like substances are di-
rectly released into the systemic circulation through the ovar-
ian venous system, bypassing hepatic deactivation. Carcinoid
syndrome is less common in the other subtypes (13 % in
trabecular and 3.2 % in strumal carcinoids) [16].
Trabecular carcinoid constitutes the second most common
ovarian carcinoid tumour and 25 % of patients will present
with constipation due to peptide YY production, which in-
hibits intestinal motility [15, 17]. Some cases of hirsutism
are also thought to be related to peptide YYproduction, which
is known to inhibit peripheral steroid-producing cells [14, 19].
Mucinous carcinoids are rare (1.5 %), may be pure or as-
sociated with mature teratomas. In these cases, the differential
diagnosis must include metastasis from a gastrointestinal tu-
mour and primary mucinous appendiceal carcinoid [1].
We should also consider strumal carcinoids, tumours that
contain normal thyroid and carcinoid tissues [21]. Eight per
cent of the patients may present with thyroid hormone-related
symptoms and some ovarian strumal carcinoids are also re-
ported to cause severe constipation owing to peptide YYpro-
duction [15, 22].
Primary carcinoid tumours typically behave in a benign
fashion, and the prognosis is generally favourable. If the tu-
mour presents with stage I, survival may be greater than 90%;
however, for women with advanced stage disease, the prog-
nosis is poor and the 5-year survival is approximately 33 %.
Attending to the more favourable prognosis of ovarian carci-
noid tumours, the differentiation of such lesions from other
Table 1 Histological classification of NE tumours. Table created by the
authors based on the literature review [1–4, 7]
Poorly differentiated
neuroendocrine carcinomas
(NECs)
Small cell carcinoma
Large cell neuroendocrine carcinoma
Well-differentiated
neuroendocrine tumours
(NETs)
Typical carcinoid
Atypical carcinoid
Combination of NE and
non-NE features
Mixed exocrine-endocrine carcinoma
(MEEC) (adeno) carcinoma with
(focal) NE differentiation
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highly malignant ovarian neoplasms is mandatory in order to
choose the most appropriate therapeutic options. Particular
note should be taken in relation to mucinous carcinoid, which
behaves more aggressively and may present with extra-
ovarian spread and lymph node involvement [14].
While performing the diagnosis of an ovarian carcinoid, it
is important to rule out ovarian metastases, essentially from
the gastrointestinal tract. The insular and trabecular subtypes
most commonly have metastases in the ovary simulating a
primary tumour. Metastatic carcinoid is frequently bilateral,
while primary ovarian carcinoids tend to be unilateral [1, 23].
Robboy et al. [24] compared the features of primary insular
carcinoids and metastatic midgut carcinoids and concluded that
the presence of extra-ovarian tumour, bilaterality,
multinodularity, vascular invasion and the absence of
teratomatous elements are suggestive of an extra-ovarian origin
[5].
Poorly differentiated neuroendocrine carcinomas (NECs)
Both small cell carcinoma and large cell NE carcinoma of the
ovary are highly malignant and aggressive, regardless of the
stage [1].
Ovarian small cell carcinoma resembles the pulmonary
type and is often associated with common epithelial tumours,
typically an endometrioid carcinoma, suggesting an origin
from ovarian surface epithelium. Its immune profile includes
positivity for neuron-specific enolase and less commonly for
chromogranin [1, 5].
Large cell NE carcinomas have been associated with be-
nign and malignant surface epithelial-stromal tumours, and
immunohistochemical markers for chromogranin are typically
positive [25, 26].
We review three cases of neuroendocrine ovarian tumours,
one primary carcinoid and two secondary carcinoid tumours
(Figs. 1, 2 and 3). Once again, we emphasise that few data are
provided in the literature regarding the imaging features of these
tumours. However, globally our findings match the literature
concepts. All the cases show well-circumscribed, predominately
solid ovarian tumours. However, Fig. 1 exemplifies a typical
benign behaviour, while Fig. 3 shows several imaging criteria
of malignant, metastatic disease. Figure 2 represents an atypical
presentation of metastatic disease, with overlap between benign
and malignant features.
Cervix
The most common NE cervical tumour is small cell carcino-
ma. Large cell NE carcinoma and carcinoid types are rarer
than the former and few data can be found in the literature.
Poorly differentiated neuroendocrine carcinomas (NECs)
As previously established, NECs encompass small cell
carcinoma and large cell NE carcinoma. Staging and
treatment strategies for both small and large cell cervi-
cal carcinoma globally follow the same criteria used
for common histological types of cervical carcinomas
[1].
Small cell carcinoma accounts for 1–6 % of cervical carcino-
mas [6, 27].Median age of diagnosis is in the 5th decade, ranging
from 21 to 87 years. Its clinical presentation is non-specific,
typically including vaginal bleeding. Some patients present with
a cervical mass and an abnormal Pap smear may be found. This
tumour is strongly associated with human papilloma virus 18
(HPV-18), but HPV-16-positive tumours have also been demon-
strated [28].
Rarely, paraneoplastic manifestations due to ectopic
hormone production may appear. The most commonly
found are hypercalcaemia (parathormone), hypoglycaemia
(insulin), carcinoid syndrome (serotonin), Cushing’s syndrome
(corticotropin), SIADH (vasopressin) and myasthenia gravis
[29].
Most tumours are voluminous, exceeding 6 cm, and
show deep cervical infiltration and necrosis. Often,
growth may be exophytic, which appears to be associ-
ated with a better prognosis [6]. Nevertheless, it is gen-
erally a highly aggressive tumour with a worse progno-
sis than that of poorly differentiated squamous cell car-
cinomas. The rates of lymphovascular space invasion
and extra-pelvic recurrences for bone, supraclavicular
lymph nodes and lung are particularly high [6, 27, 28,
30]. According to McCusker et al., females with small
cell tumours have 1.84 times greater risk of death com-
pared to patients with squamous cell carcinomas [31].
Large cell neuroendocrine carcinoma of the cervix is a rare,
aggressive tumour. It appears to have a similar outcome to
small cell carcinoma and its treatment remains challenging
because of the high rate of recurrence and distant metastases
even with early stage disease [2, 32]. The most frequent met-
astatic sites include the central nervous system, lung and bone
[33].
We review three cases of cervical small cell carcinoma
(Figs. 4, 5 and 6). Cervical NECs resemble cervical squa-
mous cell carcinoma, displaying the same MRI features:
low signal intensity on T1-weighted images (T1WI) and
high signal intensity on T2-weighted images (T2WI). No
histological distinction can be provided regarding only im-
aging features. However, according to the literature, cervi-
cal NECs are generally highly aggressive and expected to
be diagnosed in advanced FIGO stages. Concordantly, we
illustrate NECs in IV-A (invasion of adjacent organs)
(Fig. 4) and III-B (invasion of the pelvic side wall)
(Fig. 6) stages.
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Fig. 2 a–dMetastatic ovarian carcinoid of unknown primary origin in a
23-year-old female complaining of pelvic pain and amenorrhoea. Sagittal
T2-weighted MR image (a) and axial T1-weighted MR image with fat
saturation, after intravenous gadolinium administration (b). Large, well-
defined solid lesion of the left ovary, cranially and anteriorly located in
relation to the uterus. On T2WI, it displays intermediate signal intensity
and shows a central high signal region. The lesion shows peripheral,
intense contrast enhancement and a large central area of necrosis. Inferi-
orly to the solid tumour, a large simple cyst is found. A small amount of
ascites is found in the cul-de-sac. H&E section of the ovary occupied by a
tumour with insular pattern composed by neuroendocrine cells (c). These
cells have intense cytoplasmatic staining for synaptophysin (d) and have
small chromogranine-positive granules in the cytoplasm (not shown)
Fig. 1 a–e Struma carcinoid of the right ovary. A 49-year-old female
complaining of pelvic and lower abdominal pain. Ultrasound (a) and
axial enhanced CT image (b). Large, heterogeneous, mixed tumour of
the ovary, predominantly solid, with necrotic areas and calcifications. The
solid portions are moderately echogenic on US and hyperdense on
enhanced CT, while cystic areas are anechogenic on US and hypodense
on CT. No ascites are found. This tumour is composed of areas of thyroid
tissue and carcinoid (H&E), the latter having acinar and trabecular archi-
tecture (c). The neuroendocrine cells have very uniform nuclei and scarce
cytoplasm. The tumour cells show positive cytoplasmatic staining for
chromogranine (d) and for synaptophysin (not shown). The thyroid area
with compact folicular structure presents intense immunoreactivity for
thyroglobulin (e)
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Well-differentiated neuroendocrine tumours (NETs)
Well-differentiated neuroendocrine tumours (NETs) include typ-
ical and atypical carcinoid tumours. Among the uncommon sites
of primary carcinoid tumours, the uterine cervix constitutes one
of the rarest locations, representing only 0.5% to 5% of cervical
cancers. The most common symptom is also vaginal bleeding.
Carcinoid syndrome is very rare and even in the lack of clini-
cally evident carcinoid syndrome, many patients present with
elevated urinary 5-hydroxyindoleacetic acid (5-HIAA). Howev-
er, the diagnosis of a cervical carcinoid is frequently postopera-
tive and laboratorial investigation is typically not helpful since it
is not performed in the absence of symptoms. These tumours
display a very aggressive, malignant behaviour, and their prog-
nosis is poor (2- or 3-year survival rates, ranging from 12.5 to
33 %, according to some studies). This emphasises the impor-
tance of early diagnosis and treatment [14].
Atypical carcinoids of the cervix are also very rare and,
according to a review of Yoshida et al. [34], only 13 cases
have been reported in the literature.
Endometrium
The reported endometrial neoplasms with NE differentiation
essentially include small cell carcinoma and endometrial ade-
nocarcinoma with NE cells [5].
Small cell carcinoma of the endometrium resembles that of
the lung and is uncommon, accounting for less than 1 % of all
endometrial carcinomas. Nonetheless, more than 50 cases
have been reported in the literature. The age of diagnosis
ranges from 23 to 78 years old. Like in other endometrial
carcinomas, abnormal bleeding is the primary presenting
symptom, but some patients present with advanced disease,
sometimes with pain frommetastases [5]. These tumours usu-
ally present as bulky intraluminal masses, and deep
myometrial invasion (33–50%) and extra-uterine spread (near
50 %) are common. Pelvic lymph nodes, adnexa and the peri-
toneum constitute the typical sites of extra-uterine involve-
ment. The overall prognosis is poor [5, 35].
In 50 to 66%, endometrial small cell carcinoma displays an
admixed component of grade 1 or 2 endometrioid
Fig. 4 a–b Cervical neuroendocrine tumour (FIGO IV-A; invasion of
adjacent organs). A 32-year-old female complaining of vaginal bleeding
after intercourse and fetid vaginal discharge. Sagittal T2-weighted MR
image (a) and axial T2-weighted MR image (b). Large cervical cancer
with infiltration of the lower segment of the uterine corpus. The
parametria are circumferentially infiltrated and the tumour extends ante-
riorly to the bladder, with transmural invasion and fistulae (arrow). Bilat-
eral, nodal metastases of the external iliac groups are also seen
(arrowheads)
Fig. 3 a–bMetastatic, bilateral
ovarian carcinoid, from a primary
jejunal tumour in a 28-year-old
female complaining of pelvic pain
and dyspareunia. Coronal (a) and
axial (b) enhanced CT images.
Multinodular, heterogeneous and
bilateral ovarian tumour, with
moderate enhancement after
contrast administration. Ascites
are found in the pelvis and
parieto-colic gutters. Multiple
liver metastases were also seen
(not shown)
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adenocarcinoma, and few cases showed a malignant
mixed mullerian tumour within a predominant small cell
carcinoma [5].
We review two cases of poorly differentiated endometrial
carcinoma with NE differentiation (Figs. 7 and 8). Like in
cervical carcinoma, imaging does not allow histological dis-
tinction, since all endometrial cancers tend to present similar-
ly: low to moderate signal on T2WI and hypointensity relative
to the hyperintense enhancing myometrium on dynamic
contrast-enhanced MRI sequences. However, when a highly
aggressive endometrial tumour is found, a neuroendocrine
nature may be suspected. There are no consistent data
regarding the prognosis of non-pure NE endometrial tumours;
however, the cases we illustrate were diagnosed in advanced
FIGO stages, IV-B (distant metastases) (Fig. 7) and III-C1
(involvement of pelvic nodes) (Fig. 8).
Other locations
Neuroendocrine tumours of the fallopian tube, vagina
and vulva are very rare and only a few cases have been
reported [5].
Fig. 5 a–e Cervical small cell carcinoma (FIGO II-A; invasion of the
upper two-thirds of vagina with no parametrial invasion). A 41-year-old
female complaining of vaginal bleeding after intercourse. Sagittal T2-
weighted MR image (a), axial T2-weighted MR images (b) and sagittal
diffusion weighted image (DWI), b–(c) Retroverted uterus with an
anterior cervical tumour, highly restrictive on DWI. No parametrial
invasion is noted, but huge, bilateral obturator lymph nodes are found
(arrows). The left ovary shows follicular activity and is posteriorly
displaced (arrowhead). In this H&E section the cervix is occupied by a
solid tumour, composed of small cells, with uniform nuclei and scarce
cytoplasm (d). Some tumour cells show positive cytoplasmatic staining
for synaptophysin (e) and for chromogranin (not shown)
Fig. 6 a–b Cervical small cell carcinoma (FIGO III-B; extension to the
pelvic side wall). A 64 year-old female complaining of menorrhagia.
Axial T2-weighted MR image (a) and axial T1-weighted MR image with
fat saturation after intravenous gadolinium administration (b). Cervical
tumour extending posteriorly to the pelvic wall (asterisk) and superiorly
to the left adnexal area, where it forms a huge solid, heterogeneous mass
with central necrotic areas (arrow). This mass shows intense enhance-
ment after gadolinium administration and is adherent to the uterine cor-
pus, which may be found inferiorly. Bilateral internal iliac lymph nodes
are also noted (arrowheads)
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In the fallopian tube, these tumours encompass carcinoids
and small cell carcinoma, and they are not well known. In the
vagina, almost ten cases of small cell carcinoma have been
reported, occurring in females between 41 and 78 years of age.
Like in other vaginal tumours, the most frequent complaint
was vaginal bleeding or discharge. Metastatic disease was
Fig. 7 a–d Poorly differentiated endometrial carcinoma with NE
differentiation (FIGO IV-B; distant metastases). A 61-year-old female
complaining of metrorrhagia. Axial T2-weighted MR image (a) and axial
enhanced CT image (b). Large endometrial tumour invading the
myometrium, serosa and surrounding adipose tissues. There is no
invasion of the cervical stroma or bladder (not shown), but a right
obturator node (arrow) is found. CT evaluation shows that the disease
has disseminated outside the pelvis, revealing para-aortic lymph nodes
(arrowhead) as well as retroperitoneal and peritoneal metastases
(asterisks). Vagina biopsy (H&E) infiltrated by a solid tumour composed
by sheets of uniform cells, with small oval nuclei and scarse cytoplasm
(c). These cells have an intense cytoplasmatic staining for neuron-specific
enolase (d) and have small chromogranine-positive granules in the cyto-
plasm (not shown). This tumour was synaptophysin negative
Fig. 8 a–d Undifferentiated endometrial carcinoma with NE
differentiation (FIGO III-C1; involvement of pelvic nodes). A 67-year-
old female complaining of metrorrhagia. Axial T2-weighted MR images
(a, b). Endometrial tumour prolapsing into the cervical canal, without
invasion of the cervical stroma and myometrium. The tumour extends
bilaterally through the lumen of the tubes to the parametrial tissues
(arrows). A left obturator lymph node is also seen (arrowhead). H&E
section of the tumour with a solid pattern composed by large cells with
pleomorphic nuclei, mitoses and scarce cytoplasm (c). These cells have
small chromogranine-positive granules (d) and small synaptophysin
granules in the cytoplasm (not shown) and are strongly positive for
pancytokeratin CAM 5.2 (not shown)
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common in this small cohort, so the prognosis is thought to be
poor. In the vulva, neuroendocrine differentiation may be
found in small cell carcinoma of the Bartholin gland and
Merkel cell tumours, which tend to present as vulvar masses
[5].
Conclusion and teaching points
NE tumours of the female genital tract are rare, either primary
or secondary. Two groups are currently considered: NECs,
including small cell carcinoma and large cell NE carcinoma,
and NETs, which encompass typical and atypical carcinoids.
The clinical features of theses tumours are non-specific and
depend on the organ of origin and on the extension and ag-
gressiveness of the disease. The imaging evaluation should
follow the same criteria used for other tumours, and FIGO
remains the preferred staging system. The diagnosis is obvi-
ously histological, and the role of imaging tools essentially
includes initial detection, staging and biopsy guidance. How-
ever, some points should be taken into account when imaging
studies are performed:
– Cervical small cell carcinoma and ovarian carcinoid are
the most common gynaecological NE tumours.
– Cervical small cell carcinomas usually behave
aggressively.
– Ovarian carcinoids tend to behave in a benign fashion.
– While managing an ovarian carcinoid, extra-ovarian ex-
tension, bilaterality and multinodularity should raise the
suspicion of metastatic disease.
– Endometrial NE tumours are very rare and are usually
small cell carcinoma or adenocarcinoma with NE
differentiation.
– As for other tumours, US, CT, PET-CT and MRI remain
the most commonly used imaging tools, but octreotide
scans may be useful for typical and atypical carcinoids.
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